Transgene and Roche entered into license agreement for Transgene’s TG400 I, which is in phase 2 clinical trials for treating anti-HPV cancer vaccine...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: PharmaDeals Ltd